blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3411408

EP3411408 - ANTI-ROR1 ANTIBODIES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.10.2022
Database last updated on 16.09.2024
FormerThe patent has been granted
Status updated on  05.11.2021
FormerGrant of patent is intended
Status updated on  17.06.2021
FormerExamination is in progress
Status updated on  25.05.2021
FormerGrant of patent is intended
Status updated on  21.01.2021
FormerExamination is in progress
Status updated on  09.12.2019
FormerRequest for examination was made
Status updated on  09.11.2018
FormerThe international publication has been made
Status updated on  11.08.2017
Formerunknown
Status updated on  27.02.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Fred Hutchinson Cancer Center
1100 Fairview Avenue North
Seattle, WA 98109 / US
[2022/24]
Former [2018/50]For all designated states
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North
Seattle, WA 98109 / US
Inventor(s)01 / BALAKRISHNAN, Ashwini
2904 4th Avenue W.
Seattle, Washington 98119 / US
02 / HOFFSTROM, Benjamin, G.
1608 E. Republican Street
Apartment 301
Seattle, Washington 98122 / US
03 / RANDOLPH-HABECKER, Julie
9721 12th Avenue NW
Seattle, Washington 98117 / US
04 / RIDDELL, Stanley, R.
1763 268th Place SE
Sammamish, Washington 98075 / US
 [2018/50]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2018/50]
Application number, filing date17705745.202.02.2017
[2018/50]
WO2017US16300
Priority number, dateUS201662290337P02.02.2016         Original published format: US 201662290337 P
US201662324876P19.04.2016         Original published format: US 201662324876 P
[2018/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017136607
Date:10.08.2017
Language:EN
[2017/32]
Type: A1 Application with search report 
No.:EP3411408
Date:12.12.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 10.08.2017 takes the place of the publication of the European patent application.
[2018/50]
Type: B1 Patent specification 
No.:EP3411408
Date:08.12.2021
Language:EN
[2021/49]
Search report(s)International search report - published on:EP10.08.2017
ClassificationIPC:C07K16/28, A61P1/18, A61P11/00, A61P15/00, A61P35/00, A61P35/02, A61P35/04
[2020/51]
CPC:
C07K16/2803 (EP,US); A61K39/4611 (EP); A61K39/4631 (EP);
A61K39/464462 (EP); A61P1/18 (EP); A61P11/00 (EP);
A61P15/00 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P35/04 (EP); G01N33/57492 (US); C07K14/7051 (EP);
C07K2317/24 (US); C07K2317/33 (EP,US); C07K2317/34 (EP,US);
C07K2317/622 (US); C07K2317/92 (US); C07K2319/03 (EP);
G01N2333/70503 (US) (-)
Former IPC [2018/50]C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/50]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ANTI-ROR1-ANTIKÖRPER UND VERWENDUNGEN DAVON[2018/50]
English:ANTI-ROR1 ANTIBODIES AND USES THEREOF[2018/50]
French:ANTICORPS ANTI-ROR1 ET UTILISATIONS ASSOCIÉES[2018/50]
Entry into regional phase31.07.2018National basic fee paid 
31.07.2018Designation fee(s) paid 
31.07.2018Examination fee paid 
Examination procedure31.07.2018Examination requested  [2018/50]
31.07.2018Date on which the examining division has become responsible
21.03.2019Amendment by applicant (claims and/or description)
12.12.2019Despatch of a communication from the examining division (Time limit: M04)
22.04.2020Reply to a communication from the examining division
22.01.2021Communication of intention to grant the patent
25.05.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.06.2021Communication of intention to grant the patent
27.10.2021Fee for grant paid
27.10.2021Fee for publishing/printing paid
27.10.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21204990.2  / EP4006056
Opposition(s)09.09.2022No opposition filed within time limit [2022/46]
Fees paidRenewal fee
27.02.2019Renewal fee patent year 03
27.02.2020Renewal fee patent year 04
25.02.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.02.2017
AL08.12.2021
AT08.12.2021
CY08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
MK08.12.2021
MT08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
TR08.12.2021
IE02.02.2022
LU02.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
[2024/42]
Former [2024/29]HU02.02.2017
AL08.12.2021
AT08.12.2021
CY08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
MK08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
TR08.12.2021
IE02.02.2022
LU02.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2024/22]HU02.02.2017
AL08.12.2021
AT08.12.2021
CY08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
MK08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
IE02.02.2022
LU02.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2024/20]HU02.02.2017
AL08.12.2021
AT08.12.2021
CY08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
IE02.02.2022
LU02.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2024/18]HU02.02.2017
AL08.12.2021
AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
IE02.02.2022
LU02.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2023/10]AL08.12.2021
AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
IE02.02.2022
LU02.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2023/09]AL08.12.2021
AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
IE02.02.2022
LU02.02.2022
CH28.02.2022
LI28.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2023/01]AL08.12.2021
AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SI08.12.2021
SK08.12.2021
SM08.12.2021
LU02.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2022/49]AL08.12.2021
AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
LU02.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2022/47]AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
LU02.02.2022
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2022/46]AT08.12.2021
CZ08.12.2021
DK08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2022/44]AT08.12.2021
CZ08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
MC08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2022/42]AT08.12.2021
CZ08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
IS08.04.2022
PT08.04.2022
Former [2022/36]AT08.12.2021
CZ08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
NL08.12.2021
PL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
PT08.04.2022
Former [2022/35]CZ08.12.2021
EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
NL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SK08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
PT08.04.2022
Former [2022/34]EE08.12.2021
FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
NL08.12.2021
RO08.12.2021
RS08.12.2021
SE08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
PT08.04.2022
Former [2022/33]FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
NL08.12.2021
RS08.12.2021
SE08.12.2021
SM08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
Former [2022/30]FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
NL08.12.2021
RS08.12.2021
SE08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
Former [2022/25]FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
RS08.12.2021
SE08.12.2021
BG08.03.2022
NO08.03.2022
GR09.03.2022
Former [2022/24]FI08.12.2021
HR08.12.2021
LT08.12.2021
LV08.12.2021
RS08.12.2021
SE08.12.2021
BG08.03.2022
GR09.03.2022
Former [2022/22]FI08.12.2021
LT08.12.2021
RS08.12.2021
BG08.03.2022
Former [2022/21]RS08.12.2021
BG08.03.2022
Former [2022/19]BG08.03.2022
Cited inInternational search[X]  - YANG J ET AL, "Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies", vol. 6, no. 6, doi:10.1371/JOURNAL.PONE.0021018, ISSN 1932-6203, (20110601), pages E21018.1 - E21018.15, PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, URL: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0021018, (20110615), XP002670875 [X] 71-80 * abstract *

DOI:   http://dx.doi.org/10.1371/JOURNAL.PONE.0021018
 [XY]  - AMIR H DANESHMANESH ET AL, "Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 123, no. 5, doi:10.1002/IJC.23587, ISSN 0020-7136, (20080901), pages 1190 - 1195, (20080610), XP002622341 [X] 2,21 * see paragraph "Production of anti-ROR1 and specificity testing" page 1191, RH column; see paragraph "Surface staining and flow cytometry" and "Dual color fluorescence in situ hybridization" page 1192, RH column; paragraph Discussion on page 1194, RH column, second paragraph * [Y] 1,3-20,22-70,81-87

DOI:   http://dx.doi.org/10.1002/ijc.23587
 [XY]  - Daneshmanesh, "Phone ROR1 antibody (Receptor Tyrosine Kinase-Like Orphan Receptor 1) (C-Term) Antigen: Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) 2 Images available", (20081231), URL: https://www.ncbi.nlm.nih.gov/pubmed/18546292, (20170419), XP055365338 [X] 2,21 * see Item "immunogen" * [Y] 1,3-20,22-70,81-87
 [XY]  - Anonymous, "Product Datasheet: ARP63925_P050 - ROR1 Antibody - C-terminal region (ARP63925_P050) - Aviva Systems Biology", (20160101), URL: http://www.avivasysbio.com/sd/tds/html_datasheet.php?sku=ARP63925_P050, (20170419), XP055365381 [X] 2,21 * the whole document * [Y] 1,3-20,22-70,81-87
by applicantCA114536
 CA138293
 US5283173
 US5468614
 US2013251642
 WO2014031687
 US9163258
    - HUDECEK ET AL., BLOOD, (2010), vol. 116, page 4532
    - HUDECEK ET AL., BLOOD, (2010), vol. 116, pages 4532 - 41
    - YANG ET AL., PLOS ONE, (2011), vol. 6, page E21018
    - HUDECEK ET AL., CLIN. CANCER RES, (2013), vol. 19, page 3153
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1977), vol. 25, page 3389
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, page 403
    - GHAHROUDI ET AL., FEBS LETTERS, (1997), vol. 414, page 521
    - VINCKE ET AL., J. BIOL. CHEM., (2009), vol. 284, page 3273
    - HAMERS-CASTERMAN ET AL., NATURE, (1993), vol. 363, page 446
    - NGUYEN ET AL., J. MOL. BIOL., (1998), vol. 275, page 413
    - ROUX ET AL., PROC. NAT'L. ACAD. SCI. (USA), (1998), vol. 95, page 11804
    - NGUYEN ET AL., IMMUNOGENETICS, (2002), vol. 54, page 39
    - HERRIN ET AL., PROC. NAT'L. ACAD. SCI. (USA, (2008), vol. 105, page 2040
    - ALDER ET AL., NATURE IMMUNOL., (2008), vol. 9, page 319
    - JESPERS ET AL., NATURE BIOTECHNOL., (2004), vol. 22, page 1161
    - CORTEZ-RETAMOZO ET AL., CANCER RES., (2004), vol. 64, page 2853
    - BARAL ET AL., NATURE MED., (2006), vol. 12, page 580
    - BARTHELEMY ET AL., J. BIOL. CHEM., (2008), vol. 283, page 3639
    - AL-LAZIKANI ET AL., J. MOL. BIOL., (1997), vol. 273, pages 927 - 948
    - MACCALLUM ET AL., J. MOL. BIOL., (1996), vol. 262, pages 732 - 745
    - LEFRANC MP ET AL., DEV. COMP. IMMUNOL., (2003), vol. 7, pages 55 - 77
    - J. MOL. BIOL., (2001), vol. 309, pages 657 - 70
    - CAPON ET AL., NATURE, (1989), vol. 337, page 525
    - SCATCHARD ET AL., ANN. N.Y. ACAD. SCI., (1949), vol. 51, page 660
    - WILSON, SCIENCE, (2002), vol. 295, page 2103
    - WOLFF ET AL., CANCER RES., (1993), vol. 53, page 2560
    - YANG ET AL., PLOSONE, (2011), vol. 6, page E21018
    - HUDECEK ET AL., CLIN. CANCER RES., (2013), vol. 19, page 3153
    - SCHOLTEN ET AL., CLIN. IMMUNOL., (2006), vol. 119, pages 135 - 145
    - KIM ET AL., PLOS ONE, (2011), vol. 6, page E18556
    - NUCLEIC ACIDS RES., (2001), vol. 29, page E45
    - ZHANG ET AL., SCI. REP., (2014), vol. 24, page 5811
    - DAVE ET AL., PLOS ONE, (2012), vol. 7, page E52655
    - YAMAGUCHI ET AL., CANCER CELL, (2012), page 348
    - ZHANG ET AL., AM. J. PATHOL., (2012), vol. 181, page 1903
    - LEISEGANG ET AL., J. MOL. MED., (2008), vol. 86, page 573
    - BERGER ET AL., CANCER IMMUNOL. RES., (2015), vol. 3, page 206
    - ZHANG ET AL., SCIENTIFIC REPORTS, (2014), vol. 4, page 5811
    - ZHANG ET AL., PLOS ONE, (2012), vol. 7, page E31127
    - CUI ET AL., CANCER RESEARCH, (2013), vol. 73, page 3649
    - CHIEN ET AL., VIRCHOWS ARCHIV, (2016), vol. 468, page 589
    - YAMAGUCHI ET AL., CANCER CELL, (2012), vol. 21, page 348
    - KARACHALIOU ET AL., TRANSLATIONAL LUNG CANCER RESEARCH, (2014), vol. 3, page 122
    - ZHANG ET AL., THE AMERICAN JOURNAL OF PATHOLOGY, (2012), vol. 181, page 1903
    - LIU ET AL., PLOS ONE, (2015), vol. 10, page E0127092
    - MORGAN ET AL., MOLECULAR THERAPY, (2010), vol. 18, page 843
    - LAMERS ET AL., MOLECULAR THERAPY, (2013), vol. 21, page 904
    - HASSAN ET AL., CLINICAL CANCER RESEARCH, (2007), vol. 13, page 5144
    - BASKAR ET AL., CLINICAL CANCER RESEARCH, (2008), vol. 14, page 396
    - FUKUDA ET AL., PNAS, (2008), vol. 105, page 3047
    - CHOI ET AL., CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA, (2015), vol. 15, page S167
    - BERGER ET AL., CANCER IMMUNOLOGY RESEARCH, (2015), vol. 3, page 206
    - KAUCKA ET AL., ACTA PHYSIOLOGICA, (2011), vol. 203, page 351
    - HUDECEK ET AL., CLINICAL CANCER RESEARCH, (2013), vol. 19, page 3153
    - ZARITSKAYA ET AL., EXPERT REVIEW OF VACCINES, (2010), vol. 9, page 601
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.